top of page

Learning Objectives

The below learning objectives are for the overall 26th MAD-ID Annual Antimicrobial Stewardship Meeting. Session-specific learning objectives can be found on the agenda. Upon completion of the program learners will be able to: 

​

Depending on which of the four classroom/workshop sessions the participant attends, four of the following eight global learning objectives should be achieved:

​

  • Apply appropriate theoretical frameworks and research standards to the scholarship of teaching and learning in infectious diseases

  • Describe the importance of and requirements for developing and maintaining institutional antibiograms

  • Identify strategies and challenges in gathering and submitting data elements for the National Healthcare Safety Network (NHSN) Antimicrobial Use (AU) and Antimicrobial Resistance (AR) options

  • Discuss approaches to launch or expand an antibiotic stewardship program in a community hospital setting

  • Discuss challenges that impact the ability of rapid diagnostics to improve patient outcomes

  • Describe implementation strategies and approaches to measure success and feedback for continuous quality improvement in antimicrobial stewardship

  • Identify best practices for preparing for antimicrobial drug shortages

  • Discuss best practices for optimizing and standardizing monitoring in outpatient parenteral antimicrobial therapy settings

 

The following global learning objectives apply to the keynote and plenary sessions:

​

  • Describe the relationship between the microbiome and human diseases

  • Discuss the importance of pharmacokinetics/pharmacodynamics in antimicrobial drug development and improving patient outcomes

  • Compare and contrast current and emerging antifungal therapies

  • Describe examples of successful application of artificial intelligence in infectious diseases and antimicrobial stewardship

  • Discuss current guideline and guidance for treatment of key gram-negative and gram-positive pathogens

  • Discuss core elements of outpatient antibiotic stewardship programs

  • Identify antimicrobial stewardship strategies and priorities in pediatric and older adult patients

  • Identify place in therapy for live biotherapeutic products for C. difficile

  • Summarize important new clinical studies or guidelines impacting antimicrobial use and resistance

  • Describe an antimicrobial stewardship strategy or priority that directly relates to your practice or institution

bottom of page